Evidence map›Paper›PMID 42209794›Full record

ArticleNature computational science2026

FLOWR: flow matching for structure-aware de novo, interaction- and fragment-based ligand generation.

Julian Cremer, Ross Irwin, Alessandro Tibo, Jon Paul Janet, Simon Olsson, Djork-Arné Clevert

Abstract read
In one paragraph

Article in Nature computational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Is AI Capable of Real-World Drug Discovery?Journal of chemical information and modeling · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. FlowMol3: flow matching for 3DDigital discovery · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Assay2Mol: Large Language Model-based Drug Design Using BioAssay Context.Proceedings of the Conference on Empirical Methods in Natural Language Processing. Conference on Empirical Methods in Natural Language Processing · 2025
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Julian Cremer *Machine Learning and Computational Sciences, Pfizer Worldwide R&D, Berlin, Germany. julian.cremer@pfizer.com.ORCID http://orcid.org/0000-0001-6319-7283
Ross Irwin *Molecular AI, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden. rossir@chalmers.se.ORCID http://orcid.org/0009-0003-0067-8313
Alessandro TiboMolecular AI, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.ORCID http://orcid.org/0000-0002-9070-740X
Jon Paul JanetMolecular AI, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.ORCID http://orcid.org/0000-0001-7825-4797
Simon OlssonDepartment of Computer Science and Engineering, Chalmers University of Technology and University of Gothenburg, Gothenburg, Sweden.ORCID http://orcid.org/0000-0002-3927-7897
Djork-Arné ClevertMachine Learning and Computational Sciences, Pfizer Worldwide R&D, Berlin, Germany.ORCID http://orcid.org/0000-0003-4191-2156

Funding

Vetenskapsrådet (Swedish Research Council) 2022-06725Vetenskapsrådet (Swedish Research Council) 2025/22-1514Vetenskapsrådet (Swedish Research Council) 2025/23-635
6 · The paper itself

Abstract

Here we introduce FLOWR, a structure-based framework for the generation and optimization of three-dimensional ligands. FLOWR integrates continuous and categorical flow matching with equivariant optimal transport, enhanced by an efficient protein pocket conditioning. Alongside FLOWR, we present SPINDR, a curated dataset comprising ligand-pocket cocrystal complexes specifically designed to address existing data quality issues. Empirical evaluations demonstrate that FLOWR surpasses current state-of-the-art diffusion- and flow-based methods in terms of PoseBusters-validity, pose accuracy and interaction recovery, while offering an inference speed-up, achieving up to 70-fold faster performance. In addition, we introduce FLOWR.MULTI, a highly accurate multi-purpose model allowing for the targeted sampling of ligands that adhere to predefined interaction profiles and chemical substructures for fragment-based design without the need of retraining or any resampling strategies. Collectively, our results indicate that FLOWR and FLOWR.MULTI represent an advancement in artificial intelligence-driven structure-based drug design, substantially enhancing the reliability and applicability of de novo, interaction- and fragment-based ligand generation in real-world drug discovery settings.

Identifiers

PMID42209794
PMCPMC13293864

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.